AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +55

AbbVie Inc. $ABBV Shares Acquired by AMG National Trust Bank

📈 AMG National Trust Bank increased its ABBV holdings by 20.2% in Q1, adding 4,710 shares.

📊 Institutional ownership of AbbVie stands at 70.23%, with Calamos Advisors holding the largest stake at 466,290 shares.

💰 UBS raised its price target to $260 and Royal Bank of Canada increased its target to $280.

📉 Wall Street Zen downgraded ABBV from 'strong-buy' to 'buy' on July 5th.

📈 AbbVie reported Q1 revenue of $15 billion, beating estimates by $278 million.

💵 The company posted EPS of $2.65, surpassing the consensus estimate of $2.59.

📉 Revenue grew 12.4% year-over-year compared to the prior period.

💸 AbbVie declared a quarterly dividend of $1.73 per share with an ex-dividend date of July 15th.

📈 The stock trades at a PE ratio of 122.20 with a market cap of $438.27 billion.

🔬 AbbVie focuses on therapies for complex conditions including immunology, oncology, and neuroscience.

Bullish Signals
  • AbbVie reported Q1 revenue of $15 billion, which exceeded analyst estimates of $14.72 billion by $278 million.
  • The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06.
  • Revenue grew 12.4% year-over-year, demonstrating strong top-line growth in its core business segments.
  • Multiple major banks including UBS and Royal Bank of Canada have raised their price targets to $260 and $280 respectively.
  • Institutional investors like Calamos Advisors and Waycross Partners have maintained or increased significant stakes in the company.
Risk Factors
  • Wall Street Zen downgraded the stock from a 'strong-buy' rating to a 'buy' rating on July 5th.
  • The stock carries a high PE ratio of 122.20, which may indicate elevated valuation relative to current earnings.
Full Analysis
Institutional investors have recently adjusted their positions in AbbVie Inc. (NYSE: ABBV), with AMG National Trust Bank increasing its stake by 20.2% to own 27,977 shares valued at $6.085 million in the first quarter. Other notable holders include Waycross Partners LLC, which owns 182,476 shares worth $41.694 million, and Calamos Advisors LLC, holding 466,290 shares valued at $106.543 million. Axecap Investments LLC significantly boosted its position by 713.2% to acquire 16,320 shares. Wall Street analysts have issued mixed but generally positive ratings for the stock, with UBS raising its price target to $260 and Royal Bank of Canada increasing its target to $280. The consensus rating is a 'Moderate Buy' with an average price target of $266.24. However, Wall Street Zen recently downgraded the stock from a 'strong-buy' to a 'buy' rating, while DZ Bank upgraded it to a 'strong-buy'. Financially, AbbVie reported Q1 earnings of $2.65 per share, beating analyst estimates of $2.59, with revenue reaching $15 billion, a 12.4% year-over-year increase. The company has a market capitalization of $438.27 billion and a PE ratio of 122.20. AbbVie also declared a quarterly dividend of $1.73 per share, payable on August 14th to shareholders of record on July 15th.